Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 16:34 ET
|
Orchestra BioMed Holdings, Inc.
U.S. Food and Drug Administration (“FDA”) granted Investigational Device Exemption (“IDE”) approval with conditions for Virtue SAB® coronary in-stent restenosis (“ISR”) U.S. pivotal study (in...
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
August 08, 2023 08:30 ET
|
Orchestra BioMed Holdings, Inc.
Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of extended release sirolimus under clinical investigation worldwideVirtue ISR-US...
Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes
June 26, 2023 08:00 ET
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., June 26, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer
June 07, 2023 08:30 ET
|
Orchestra BioMed Holdings, Inc.
Bill Little, previously Chief Operating Officer (COO) of Neovasc, Inc. through its acquisition by Shockwave Medical in April 2023, will lead efforts to forge further strategic collaborations in newly...
Orchestra BioMed to Present at the Jefferies Global Healthcare Conference
June 01, 2023 08:00 ET
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update
May 12, 2023 09:15 ET
|
Orchestra BioMed Holdings, Inc.
Completed business combination and listing on Nasdaq generating gross proceeds of approximately $70 millionBackBeat CNT™ global pivotal study in hypertensive pacemaker patients on track for initiation...
Orchestra BioMed to Present at Upcoming Investor Conferences
March 07, 2023 08:00 ET
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023
February 24, 2023 08:00 ET
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
Orchestra BioMed Strengthens Senior Leadership Team
February 07, 2023 08:00 ET
|
Orchestra BioMed Holdings, Inc.
Avi Fischer, M.D., joins as SVP, Medical Affairs and Innovation; J.C. Simeon assumes role of SVP, Quality George Papandreou, Ph.D., promoted to General Manager and SVP, Focal Therapies; Kunal Faldu...
Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model
January 27, 2023 08:00 ET
|
Orchestra BioMed, Inc.
Business combination with Health Sciences Acquisitions Corporation 2, a special purpose acquisition company sponsored by an affiliate of RTW Investments, LP, completed on January 26, 2023 The...